Laura D J Antipov

This inventor holds 5 USPTO granted patents. Top assignee: Silver Creek Pharmaceuticals, Inc.. Active years: 2018-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laura D J Antipov. Retrieved from https://idiyas.com/inventor/laura-d-j-antipov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 12(Granted Patents)

Company Filing History:

5 out of 10

Silver Creek Pharmaceuticals, Inc.

patents

Years Active: 2018-2024

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12122819 - Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant (2024-10-22),

2. 11879002 - Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof (2024-01-23),

3. 11155593 - Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5 (2021-10-26),

4. 10633425 - Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5 (2020-04-28),

5. 10040840 - Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue (2018-08-07),

Title: Innovations in Regenerative Medicine: The Patents of Laura D J Antipov

Introduction

Laura D J Antipov is an accomplished inventor based in Oakland, California, known for his significant contributions to the field of regenerative medicine. With a total of five patents to his name, Antipov has demonstrated a profound understanding of bi-specific fusion proteins and their applications in treating tissue damage.

Latest Patents

Among his latest innovations, Antipov has developed a method for treating skin tissue damage by topically administering a bi-specific protein. This innovative approach combines a human insulin-like growth factor variant with a human annexin A5 variant, providing new avenues for repairing or regenerating damaged or diseased tissue. Furthermore, he has contributed to the field through his work on bi-specific fusion proteins that include pharmaceutical compositions and methods to utilize these proteins effectively.

Career Highlights

Antipov is currently associated with Silver Creek Pharmaceuticals, Inc., where his research is focused on advancing therapeutic applications of bi-specific proteins. His work has been crucial in paving the way for novel treatments that enhance healing processes and improve patient outcomes.

Collaborations

Throughout his career, Antipov has collaborated with notable colleagues such as Shawdee Eshghi and Kristopher M Kuchenbecker. These partnerships have facilitated innovative research and development efforts, further strengthening the impact of their collective work in pharmaceutical sciences.

Conclusion

Laura D J Antipov continues to be a pivotal figure in regenerative medicine, with his patents reflecting a deep commitment to improving the quality of healthcare through innovative inventions. His work not only showcases his expertise as an inventor but also highlights the importance of collaboration in advancing medical technology.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]